THE ONCOLOGY INSTITUTE, INC. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 30 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $142M | ↑+41.6% | — | — | — |
| 2025-09-30 | $137M | ↑+36.7% | $-17M | ↓-2.4% | -5.9% |
| 2025-06-30 | $120M | ↑+21.5% | $-17M | ↓-9.9% | -9.4% |
| 2025-03-31 | $104M | ↑+10.3% | $-20M | ↑+1.5% | -9.5% |
| 2024-12-31 | $100M | ↑+16.9% | — | — | — |
| 2024-09-30 | $100M | ↑+21.8% | $-16M | ↑+7.5% | -13.9% |
| 2024-06-30 | $99M | ↑+22.9% | $-15M | ↑+8.4% | -16.6% |
| 2024-03-31 | $95M | ↑+24.2% | $-20M | ↑+33.7% | -19.0% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$142M
↑+41.6% +$42M YoY
Net Income
$110M
↑+52.2% +$38M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
DFPH Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyDFPH Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics